C

    CNS Pharmaceuticals Inc (CNSP)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $5.99
    +0.47 (+8.46%)

    Market Cap: $8.07M

    Last updated: Sep 01, 2026 at 10:00 AM ET

    Earnings

    Performance (10Y)

    Beat Rate
    67%(16/24)
    Avg Surprise
    -53.55%

    Upcoming Estimates

    Sep 30, 2026
    EPS Consensus$-0.27
    Range$-0.27 - $-0.27
    1 analysts
    EPS RevisionsNo revisions (7d)No revisions (30d)
    EPS Estimate Drift
    90d ago$0.00+100.0%
    60d ago$-0.74-174.1%
    30d ago$-0.74-174.1%
    7d ago$-0.74-174.1%
    Current$-0.27
    Revenue Consensus
    $0
    Range$0 - $0
    1 analysts
    Dec 31, 2026
    EPS Consensus$4.23
    Range$4.23 - $4.23
    1 analysts
    Revenue Consensus
    $0
    Range$0 - $0
    1 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$4.23---
    Sep 26EST
    		-$-0.27---
    Jun 26
    		$-0.38$-0.24-58.33%Miss+94.1%
    Mar 26
    		$-7.30$-5.37-35.94%Miss-362.0%
    Dec 25
    		$-10.15$-5.09-99.41%Miss+72.8%
    Sep 25
    		$-5.76$-6.63+13.12%Beat+96.2%
    Jun 25
    		$-6.42$-9.60+33.13%Beat+4.5%
    Mar 25
    		$-1.58$-2.00+21.00%Beat-288.4%
    Dec 24
    		$-37.33$-7.33-409.28%Miss+99.9%
    Sep 24
    		$-150.00$-60.00-150.00%Miss+99.5%
    Jun 24
    		$-6.72$0.00N/ABeat+100.0%
    Mar 24
    		$-0.41$0.00N/ABeat+84.3%
    Dec 23
    		$-28622.96$0.00N/ABeat-748976.5%
    Sep 23
    		$-32400.01$-51900.02+37.57%Beat+60.0%
    Jun 23
    		$-31200.01N/A+63.12%Beat+61.5%
    Mar 23
    		$-2.59$0.00N/ABeat+100.0%
    Dec 22
    		$-3.82$-2.40-59.21%Miss-27.4%
    Sep 22
    		$-81000.11$-90000.13+10.00%Beat+35.7%
    Jun 22
    		$-81000.11$-72000.10-12.50%Miss+40.0%
    Mar 22
    		$-63000.09$-126000.18+50.00%Beat+53.3%
    Dec 21
    		$-3.00$-4.80+37.50%Beat+100.0%
    Sep 21
    		$-126000.18$-132000.18+4.55%Beat-16.7%
    Jun 21
    		$-135000.19$-117000.16-15.38%Beat+0.0%
    Mar 21
    		$-135000.19$-108000.15-25.00%Beat-25.0%
    Dec 20
    		$-162000.23$-105750.15-53.19%Beat-3176375.1%
    Sep 20
    		$-108000.15$-112500.16+4.00%Beat-140.0%
    Jun 20
    		$-135000.19$-72000.10-87.50%Beat-450000533.3%
    Mar 20
    		$-108000.15$-90000.13-20.00%Beat-22978655.3%
    Dec 19
    		$-5.10$-0.90-466.67%Miss-
    Sep 19
    		$-45000.06$-27000.04-66.67%Beat-
    Jun 19
    		$-0.03$0.00N/AMiss-
    Mar 19
    		$-0.47$0.00N/AMiss-

    Key Metrics

    Valuation
    P/E Ratio-0.25EV/EBITDA0.40x
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin0.00%Operating Margin0.00%
    ROE-106.60%ROICN/A
    Financial Health
    Debt/EquityN/AInterest Coverage-1116.16x
    Current Ratio5.86xQuick Ratio5.86x
    Trading Statistics
    Beta0.98Avg Volume7.63K
    52-Week High$10.5952-Week Low$1.90

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$5.77
    SMA 20$5.54
    SMA 50$5.19
    SMA 200$4.85
    EMA 10$5.68
    EMA 20$5.57
    EMA 50$5.28
    EMA 200$5.97

    MACD

    Line: 0.15Signal: 0.15Hist: -0.00

    ADX

    ADX: 21.6+DI: 20.1-DI: 14.0

    Aroon & PSAR

    Aroon Up68.0
    Aroon Down12.0
    PSAR$5.42

    Bollinger Bands

    Upper Band$6.14
    Lower Band$4.94
    %B Position2170%(Upper)
    Band Width0.87

    RSI (14-Day)

    Neutral
    58.5

    Momentum Oscillators

    Stoch %K61.7
    Stoch %D54.9
    Williams %R-14.9
    ROC (10d)10.9%
    Momentum0.59
    CCI (20d)86.5
    MFI (14d)69.2

    Volatility Measures

    ATR (14d)$0.42(7.0%)
    StdDev (20d)0.30
    Hist Vol81.4%(High)

    Volume Flow

    VWAP$5.86
    OBV164.7M
    AD Line6.7B
    CMF (20d)-0.166

    Volume Metrics

    Avg Vol (20d)7.6K
    Vol Ratio0.7x
    VWMA (20d)$5.66

    Pivot Points

    R3$6.03
    R2$5.91
    R1$5.72
    Pivot Point$5.60
    S1$5.40
    S2$5.28
    S3$5.09

    Advanced Oscillators

    TSI9.46
    Ultimate Osc40.4
    KST105.99

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$0$0$0$0$0$0$3,140$0$0$0$0$0
    Cost of Revenue$0$0$-2,898$0$0$0$985$0$0$0N/A$0
    Gross Profit$0$0$2,898$0$0$0$-985$0$0$0N/A$0
    Operating Expenses$2.70M$4.98M$5.99M$3.25M$2.41M$4.34M$3.20M$5.63M$2.53M$3.54M$5.38M$4.53M
    R&D$1.20M$3.54M$3.17M$2.20M$1.17M$3.24M$1.50M$4.24M$1.12M$2.43M$4.27M$3.41M
    SG&A$1.50M$1.43M$2.82M$1.06M$1.24M$1.09M$1.70M$1.38M$1.41M$1.11M$1.11M$1.12M
    Operating Income$-2,700,000$-4,975,205$-5,986,126$-3,253,388$-2,409,000$-4,337,660$-3,200,048$-5,628,906$-2,528,135$-3,544,854$-5,379,371$-4,533,840
    Interest Income$0$0$0$0$0$0$0$0$0$0$0$0
    Interest Expense$4,000$6,111$2,721$2,116$4,000$6,208$2,774$2,258$4,463$6,625$2,881$1,838
    Income Before Tax$-2,588,000$-4,937,046$-5,955,802$-3,218,481$-2,375,000$-4,301,320$-3,176,366$-5,605,934$-2,530,753$-3,544,748$-5,375,250$-4,522,795
    Income Tax Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Net Income$-2,588,000$-4,937,046$-5,955,802$-3,218,481$-2,375,000$-4,301,320$-3,176,366$-5,605,934$-2,530,753$-3,544,748$-5,375,250$-4,522,795
    EBITDA$-2,572,868$-4,929,067$-5,952,061$-3,215,668$-2,370,100$-4,294,012$-3,172,607$-5,602,925$-2,525,538$-3,537,305$-5,378,418$-4,520,058
    EBIT$-2,584,000$-4,930,935$-5,953,081$-3,216,365$-2,371,000$-4,295,112$-3,173,592$-5,603,676$-2,526,290$-3,538,123$-5,379,371$-4,520,957
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about CNSP

    News

    Vertical Data: Downs Most Recently Served as CFO of CNS Pharmaceuticals >VDTA

    This article from Vertical Data states that the company's new CFO, John Downs, most recently held the CFO position at CNS Pharmaceuticals. The article is very short, providing only this piece of information.

    Moomoo•8/19/26•
    Neutral

    CNS Pharmaceuticals director Michal Fisher buys $10,000 in stock By Investing.com

    Michal Fisher, a director at CNS Pharmaceuticals, Inc. (NASDAQ:CNSP), recently purchased 2,000 shares of the company's common stock for $10,000. This transaction occurred on May 18, 2026, at a price of $5.00 per share, bringing Fisher's direct holdings to 2,000 shares. The purchase follows a significant 69.8% stock surge over the last six months, and InvestingPro analysis suggests CNSP is undervalued with predictions of profitability this year.

    Investing.com South Africa•8/19/26•
    Bullish

    CNS Pharmaceuticals director Michal Fisher buys $10,000 in stock

    Michal Fisher, a director at CNS Pharmaceuticals (NASDAQ:CNSP), purchased 2,000 shares of the company's stock for $10,000 on May 18, 2026, at $5.00 per share

    Investing.com•8/18/26•
    Neutral

    CNS Pharmaceuticals director Michal Fisher buys $10,000 in stock

    Michal Fisher, a director at CNS Pharmaceuticals, Inc. (NASDAQ:CNSP), purchased 2,000 shares of the company's common stock for $10,000 on May 18, 2026, at $5.00 per share. This transaction increases Fisher's direct holdings to 2,000 shares, occurring after a significant 69.8% stock surge and with the stock currently trading near the acquisition price. InvestingPro analysis suggests CNSP is undervalued, with analysts expecting profitability this year.

    Investing.com•8/18/26•
    Bullish

    CNS Pharmaceuticals (CNSP) CEO converts 4,750 RSUs to stock

    CNS Pharmaceuticals (CNSP) CEO Rami Levin converted 4,750 Restricted Stock Units (RSUs) into common stock on August 14, 2026. These RSUs were part of a 19,000-unit grant from January 1, 2026, with a vesting schedule tied to continued employment. Following this transaction, Levin directly holds 4,750 shares of common stock and 14,250 remaining RSUs.

    Stock Titan•8/18/26•
    Neutral

    Frequently Asked Questions About CNSP

    Does CNSP pay dividends?
    CNS Pharmaceuticals Inc (CNSP) does not currently pay a regular dividend.
    What is CNSP's market cap?
    CNS Pharmaceuticals Inc (CNSP) has a market capitalization of $8.07M with a current stock price of $5.99.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In